Substack · Daily Stock Market Update · AlgoTradeAlert.com
Moderna (MRNA): Phase 3 Melanoma Results Strengthen the Oncology Case
Why it is trending
US · 2 entries · 2 publications
MRNA
Moderna, Inc.
- Entries
- 2
- Bullish
- 0
- Bearish
- 0
- First
- Feb 11, 2026
- Latest
- Oct 26, 2026
No entry states a stance.
Jan 25 – Oct 26 · per month
Full performance tracking Pro · free during launch
Alpha of every thesis on MRNA at 1, 3 and 6 months and since publication, and the full chart vs its benchmark.Free during launch: log in or sign up with your email to see it.
Sign up freeTimeline
Newest to oldest- October 2026 1 entry
- February 2026 1 entry
Substack · Force of Infection · Caitlin Rivers
FDA refuses to review Moderna’s mRNA flu vaccine application
Moderna announced this evening that the Food and Drug Administration (FDA) has refused to initiate a review of its application for an mRNA-based seasonal influenza vaccine.
Since publication +390.9% α +380.3 pp vs S&P 500 · USD
Prices as of the Oct 27, 2026 close. Past performance does not guarantee future results. Price-only, excluding dividends, in local currency. Data may be delayed or inaccurate. Not investment advice. How it is calculated.